

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-29. (Cancelled).

1 ~~30~~. (Previously Presented) A mutant antibody that comprises a mutant immunoglobulin chain, the mutant antibody having higher affinity for an antigen than a parent antibody that comprises a parent immunoglobulin chain, wherein the mutant immunoglobulin chain comprises an amino acid substitution that eliminates a variable region glycosylation site of the parent immunoglobulin chain, said elimination having the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

2 ~~31~~. (Previously Presented) The mutant antibody of claim ~~30~~, wherein the glycosylation site is an N-linked glycosylation site selected from the group consisting of:

- (1) -Asn-X-Ser-; and
- (2) -Asn-X-Thr-;

wherein X is an amino acid other than Pro.

3 ~~32~~. (Previously Presented) The mutant antibody of claim ~~30~~, wherein the glycosylation site is an O-linked glycosylation site selected from the group consisting of:

- (1) -Thr-X-X-Pro-; and
- (2) —Ser-X-X-Pro-;

wherein X is an amino acid.

4 ~~33~~. (Previously Presented) The mutant antibody of claim ~~30~~, wherein the mutant antibody is a humanized version of the parent antibody.

5 ~~34~~. (Previously Presented) The mutant antibody of claim ~~30~~, whose variable region has no glycosylation sites.

6 ~~35~~. (Previously Presented) The mutant antibody of claim ~~30~~<sup>1</sup>, whose variable region has no N-linked glycosylation sites.

7 ~~36~~. (Previously Presented) The mutant antibody of claim ~~30~~<sup>1</sup>, wherein the parent antibody is murine M195 antibody.

8 ~~37~~. (Previously Presented) The mutant antibody of claim ~~30~~<sup>1</sup>, wherein the mutant antibody is a humanized M195 antibody.

9 ~~38~~. (Previously Presented) The mutant antibody of claim ~~30~~<sup>1</sup>, wherein the antigen is a cell surface glycoprotein.

10 ~~39~~. (Previously Presented) The mutant antibody of claim ~~30~~<sup>1</sup>, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

11 ~~40~~. (Previously Presented) The mutant antibody of claim ~~30~~<sup>1</sup>, wherein the amino acid substitution is a conservative amino acid substitution.

12 ~~41~~. (Previously Presented) The mutant antibody of claim ~~31~~<sup>2</sup>, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

13 ~~42~~. (Previously Presented) The mutant antibody of claim ~~31~~<sup>2</sup>, wherein the amino acid substitution is a conservative amino acid substitution.

14 ~~43~~. (Previously Presented) The mutant antibody of claim ~~32~~<sup>3</sup>, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.

15 ~~44~~. (Previously Presented) The mutant antibody of claim ~~32~~<sup>3</sup>, wherein the amino acid substitution is a conservative amino acid substitution.

16 ~~45~~. (Previously Presented) The mutant antibody of claim 38, wherein the cell surface glycoprotein is the CD33 antigen.

<sup>1</sup>  
1746 (new) The mutant antibody of claim 30, wherein the mutation is in a complementary determining region of the parent immunoglobulin chain and the parent antibody binds an epitope of the antigen consisting of polypeptide.

1847. (new) A method for producing a mutant antibody having higher affinity for an antigen relative to a parent antibody, the method comprising

introducing a mutation into a polynucleotide sequence encoding a chain of the parent antibody, whereby the polynucleotide encodes a mutant immunoglobulin chain comprising an amino acid substitution that eliminates a variable region glycosylation site of the parent immunoglobulin chain,

expressing said mutant sequence in a cell; and

determining that said elimination has the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

<sup>18</sup>  
1948. (new) The method of claim 47, wherein the amino acid substitution is a conservative amino acid substitution.

<sup>18</sup>  
2049. (new) The method of claim 47, wherein the mutation is in a complementary determining region of the parent immunoglobulin chain and the parent antibody binds an epitope of the antigen consisting of polypeptide.